Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors.

Tanaka D, Tsuda Y, Shiyama T, Nishimura T, Chiyo N, Tominaga Y, Sawada N, Mimoto T, Kusunose N.

J Med Chem. 2011 Feb 10;54(3):851-7. doi: 10.1021/jm101273e. Epub 2010 Dec 30.

PMID:
21192659
2.
3.

Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry.

Wellenzohn B, Lessel U, Beller A, Isambert T, Hoenke C, Nosse B.

J Med Chem. 2012 Dec 27;55(24):11031-41. doi: 10.1021/jm301549a. Epub 2012 Dec 13.

PMID:
23211099
4.

Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening.

Xing L, McDonald JJ, Kolodziej SA, Kurumbail RG, Williams JM, Warren CJ, O'Neal JM, Skepner JE, Roberds SL.

J Med Chem. 2011 Mar 10;54(5):1211-22. doi: 10.1021/jm101382t. Epub 2011 Feb 8.

PMID:
21302953
5.

Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method.

Kowalski JA, Swinamer AD, Muegge I, Eldrup AB, Kukulka A, Cywin CL, De Lombaert S.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3703-7. doi: 10.1016/j.bmcl.2010.04.078. Epub 2010 Apr 22.

PMID:
20472432
6.

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.

Anandan SK, Gless RD.

Bioorg Med Chem Lett. 2010 May 1;20(9):2740-4. doi: 10.1016/j.bmcl.2010.03.074. Epub 2010 Mar 19.

PMID:
20363133
7.

Potent urea and carbamate inhibitors of soluble epoxide hydrolases.

Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD.

Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8849-54.

8.

Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening.

Amano Y, Tanabe E, Yamaguchi T.

Bioorg Med Chem. 2015 May 15;23(10):2310-7. doi: 10.1016/j.bmc.2015.03.083. Epub 2015 Apr 6.

PMID:
25862210
9.

Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD.

Biochem Pharmacol. 2002 May 1;63(9):1599-608.

PMID:
12007563
10.
11.

Fragment Screening of Soluble Epoxide Hydrolase for Lead Generation-Structure-Based Hit Evaluation and Chemistry Exploration.

Xue Y, Olsson T, Johansson CA, Öster L, Beisel HG, Rohman M, Karis D, Bäckström S.

ChemMedChem. 2016 Mar 4;11(5):497-508. doi: 10.1002/cmdc.201500575. Epub 2016 Feb 4.

PMID:
26845235
12.

3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues.

Nakagawa Y, Wheelock CE, Morisseau C, Goodrow MH, Hammock BG, Hammock BD.

Bioorg Med Chem. 2000 Nov;8(11):2663-73. Erratum in: Bioorg Med Chem 2001 Jul;9(7):1941.

PMID:
11092551
13.

Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD.

J Med Chem. 2005 May 19;48(10):3621-9.

14.

Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation.

Argiriadi MA, Morisseau C, Goodrow MH, Dowdy DL, Hammock BD, Christianson DW.

J Biol Chem. 2000 May 19;275(20):15265-70.

15.

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

Shen HC, Ding FX, Wang S, Deng Q, Zhang X, Chen Y, Zhou G, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Tsai C, Stevenson AS, Pai LY, Alonso-Galicia M, Chen X, Soisson SM, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.

J Med Chem. 2009 Aug 27;52(16):5009-12. doi: 10.1021/jm900725r.

PMID:
19645482
16.

Peptidyl-urea based inhibitors of soluble epoxide hydrolases.

Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD.

Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44.

17.

[Fragment-based drug discovery: concept and aim].

Tanaka D.

Yakugaku Zasshi. 2010 Mar;130(3):315-23. Review. Japanese.

18.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20. doi: 10.1016/j.bmcl.2009.07.138. Epub 2009 Aug 6.

PMID:
19682899
20.

Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.

Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, Zhou LM, Keyvan M, Enache L, Sullins D, Onua E, Zhang J, Halldorsdottir G, Sigthorsdottir H, Thorlaksdottir A, Sigthorsson G, Thorsteinnsdottir M, Davies DR, Stewart LJ, Zembower DE, Andresson T, Kiselyov AS, Singh J, Gurney ME.

J Med Chem. 2010 Jan 28;53(2):573-85. doi: 10.1021/jm900838g.

PMID:
19950900

Supplemental Content

Support Center